In Focus channel feed – Endpoints News

SIGN UP

In Focus channel feed

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

8 hours ago

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Yesterday

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

3 days ago

Dana-Farber, Brigham breakup could lead to a ripple effect for CGT clinical trials for cancer

Last week

In the Lab: Regeneron brings its antibody chops to gene editing's biggest problem, aiming to 'change the field'

Last week

Can Novo Nordisk's blockbuster weight loss drug and other GLP-1s also work in NASH? The answer is complicated

3 weeks ago

PacBio, once slated to be acquired by Illumina, is taking on the DNA giant

Last month

Inversago was working toward a potential 2024 IPO, but Novo’s interest won out. CB1 biotechs hope to ride the wave

Last month

His tiny prenatal testing company has big plans after exacting legal revenge on lab giants

Last month

As Vertex’s pivotal pain readout looms, non-opioid drug development faces a reckoning

Last month

‘This is not a science problem anymore': Paths emerge for scaling up rare disease medicine

2 months ago

‘The sleeping giant is waking up’: FTC raises the pressure on pharma dealmaking

3 months ago

'Moderna will be a rare disease company,' CEO says, as mRNA company plots expansion in genetic diseases and eyes n-of-1 treatments

3 months ago

Escaping an improbable upbringing, Greg Verdine places his biggest career bets in drugging the ‘undruggable’

3 months ago

Rich Horgan spearheaded a gene therapy for his brother. The trial ended in tragedy, but the work continues for more patients

4 months ago

Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out

4 months ago

CAR-T reshaped cancer treatment. Can it change autoimmune disease, too?

5 months ago

No longer ‘dead or just hibernating,’ drugmakers return to heart medicines

6 months ago

Rare disease trials can't find enough patients. It's forcing the FDA to rethink its approach

6 months ago

‘Harder to find homes’: Latest wave of biotech layoffs could test the industry

7 months ago

A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it

7 months ago

Decades after breakthrough, scientists still puzzling over mRNA delivery

7 months ago

Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up

7 months ago

How Purdue's $272M addiction payout funded a new home for its discarded non-opioid research

7 months ago

12 3 4 Next page Last page